Latest:
Cancer Hijacks Your Bone Marrow and Your Immune System: What Are You Going to Do About It?
Thomas Marron, MD, PhD, of The Tisch Cancer Institute at Mount Sinai, discusses the ways cancer attacks the bone marrow and immune system.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Thomas Powles MBBS, MRCP, MD
Latest:
Timeline of Enfortumab Vedotin in UC: From Previously Treated UC to Frontline Therapy
Thomas Powles, MBBS, MRCP, MD, discusses how antibody-drug conjugates have demonstrated improvement over chemotherapy. Data from the EV-301 trial shows that the antibody-drug conjugate enfortumab vedotin decreased the risk of death by 30% versus chemotherapy. Later trial data showed that treatment using enfortumab vedotin plus pembrolizumab (EV+P) reduced the risk of patient death by 53%.
Thomas Powles, MD, MBBS, MRCP
Latest:
Understanding Unprecedented Data in Genitourinary Cancers From ESMO 2023: Dr Powles
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Thomas S. Uldrick, MD
Latest:
Dr. Uldrick on Rituximab Plus Liposomal Doxorubicin in HIV-Infected Patients With KSHV-MCD
Thomas S. Uldrick, MD, staff clinician, HIV and AIDS Malignancy Branch, Center for Cancer Research at the National Institutes of Health, discusses long-term data from a study examining rituximab plus liposomal doxorubicin in HIV-infected patients with Kaposi sarcoma (KS) herpes virus-associated multicentric Castleman disease.
Thomas Wright, MD
Latest:
HPV Test With Genotyping Tops Cervical Cancer Screening Strategies
Cervical cancer screening based on identification of human papillomavirus (HPV) strains outperformed primary liquid cytology for detection of high-grade cervical intraepithelial neoplasia (CIN), data from a large cohort study showed.
Tianhong Li, MD, PhD
Latest:
Dr. Li Reviews Afatinib Data From the LUX-Lung 3 Trial
Tianhong (Tina) Li, MD, PhD, from the UC Davis Comprehensive Cancer Center, discusses results from the LUX-Lung 3 trial that examined afatinib as a first-line treatment for patients with EGFR-positive advanced lung adenocarcinoma.
Ticiana A. Leal, MD
Latest:
Insights from ARTEMIS-001
Panelists discuss how preliminary results from the pPhase 3 ARTEMIS-001 study indicate that iIfinatamab dDeruxtecan, a B7-H3 antibody-drug conjugate, demonstrates promising antitumor activity in relapsed small cell lung cancer, with a notable partial response rate and manageable safety profile among treated patients.